Immunologic and pharmacologic concepts of monoclonal antibodies.
While monoclonal antibodies have solved many of the difficulties of using immunologic reagents for radioimmunodiagnosis and therapy, in the 13 years since their introduction a number of persistent problems remain, most notably a low yield of antibody-producing cells from the fusion process, difficulty in obtaining high-affinity antibodies, and the potential immunogenicity of murine immunoglobulins (Igs). Several solutions are under development, including fusion techniques that enrich for cells producing desired antibodies, production of human-mouse chimeric antibodies by recombinant DNA technology, and the generation of human monoclonal antibodies by promising new approaches. Until these upcoming methodologies are established, and to better direct their development and application, a sound understanding of the pharmacology of presently available native and modified monoclonal antibodies is crucial. Although much has been already determined in this area, a great deal of further clarification remains necessary.
Zuckier
L S
LS
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461.
Rodriguez
L D
LD
Scharff
M D
MD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D006825:Hybridomas; D007120:Immunochemistry; D007553:Isotope Labeling; D013329:Structure-Activity Relationship; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal